| ALK5 | Activin receptor-like kinase 5 |
| ASO | Antisense oligonucleotide |
| ATP | Adenosine triphosphate |
| CDK | Cyclin-dependent kinase |
| CN | Carbonitrile |
| C-H | Carbon–hydrogen |
| CTLs | Cytotoxic T lymphocytes |
| DNA | Deoxyribonucleic acid |
| EMT | Epithelial–mesenchymal transition |
| EW-7197 | TGF-βR1 kinase inhibitor (compound 9) |
| GS | Glycine-serine-rich |
| H-bond | Hydrogen bond |
| IC50 | Half maximal inhibitory concentration |
| IN-1130 | TGF-βR1 kinase inhibitor (compound 7) |
| MAPK | Mitogen-activated protein kinase |
| MOE | Molecular operating environment |
| NHLF | Normal human lung fibroblast |
| NK | Natural killer (cells) |
| PD-1 | Programmed cell death protein 1 |
| PDB | Protein Data Bank |
| R1, R2, R3 | Variable substituent groups in a molecule |
| RNA | Ribonucleic acid |
| SAR | Structure–activity relationship |
| SBE | SMAD binding element |
| SMAD | Homolog of mothers against decapentaplegic (a family of signaling proteins) |
| SMI | Small molecule inhibitor |
| sTGF-βR3 | Soluble transforming growth factor beta receptor type 3 |
| TGF-β | Transforming growth factor beta |
| TGF-βR1 | Transforming growth factor beta receptor type 1 |
| TGF-βR2 | Transforming growth factor beta receptor type 2 |
| TGF-βR3 | Transforming growth factor beta receptor type 3 |